Emerging evidence highlights its therapeutic potential in bladder cancer (98), osteosarcoma (99), and colon cancer (100), positioning SERPINA1 as a dual prognostic biomarker and actionable target. The gene discussed is SERPINA1; the disease is colonic neoplasm.